Replies to post #173280 on Anavex Life Sciences Corp (AVXL)

[nidan7500]

As the a drug is proved for multiple indications with the same MOA doesn't the burden of proof become less under new FDA protocols?

Exactly correct. Indication Complexity and criticality will be factors.